Costs of misplacement
The associated global cost of the (partly avoidable) CRT misplacements is currently over €1,4 Billion (cost of the devices alone). Affected patients will have higher hospitalization rates and in the US alone, these patients have treatment-associated costs of >250 Million US$ per annum (without the cost of the devices and placement costs). Procedures to make CRT device placement more accurate and effective will therefore have major health and economic impact.
With its lead medical device product CARTBox, CART-Tech has developed a technology that can extend the benefits of CRT to a larger number of patients (see Technology). The product has received its final CE Mark in October 2019 and will be launched in the first European countries in 2020.
Impact for the patient
Patients who do not respond to CRT will continue to suffer from deteriorating heart failure, including:
- Shortness of breath (dyspnea)
- Fatigue and weakness
- Swelling (edema) in the legs, ankles and feet
- Rapid or irregular heartbeat
- Reduced ability to exercise.
They will need to visit the hospital more frequently than patients who do respond and have a poorer prognosis and life expectancy. In some non-responding patients, CARTBox may be used in the future to find out if the LV lead has been placed in a sub-optimal location and, if so, they may be are eligible for lead repositioning.
11 October 2019
CE Mark for final CARTBox product obtained
CART-Tech presents new concepts at EHRA 2019 in the Innovation stage session
on Sunday March 17
Catheterisation lab, Department of Cardiology,
Utrecht Universty Medical Center